Carcinoma of the ampulla of Vater: prognostic factors after curative surgery: a series of 45 cases.

Anne Dorandeu(Centre Hospitalier Universitaire de Rennes), B Launois(Académie Nationale de Médecine), N Leclercq-Rioux(Centre Hospitalier Universitaire de Rennes), Michel Gosselin(Université du Québec à Rimouski), Jean‐Luc Raoul(Institut de Cancérologie de l'Ouest), E. Martin(Institut de Cancérologie de l'Ouest), M.P. Ramée(Centre Hospitalier Universitaire de Rennes), Franck Siriser(Centre Hospitalier Universitaire de Rennes)
Gut
March 1, 1997
10.1136/gut.40.3.350
Cited by 36

Related Papers

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
|Journal of Clinical Oncology|2013|596
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial
|The Lancet Oncology|2014|451